Immunome Financial Statements (IMNM)
|
|
|
|
Report date
|
|
|
28.03.2022 |
16.03.2023 |
28.03.2024 |
19.03.2025 |
03.03.2026 |
|
12.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
14.0 |
9.04 |
6.94 |
|
4.02 |
|
Operating Income, bln rub |
|
|
-25.2 |
-36.9 |
-109.5 |
-305.8 |
-214.1 |
|
-238.8 |
|
EBITDA, bln rub |
? |
|
-24.4 |
-36.3 |
-28.0 |
-151.4 |
-211.2 |
|
-233.3 |
|
Net profit, bln rub |
? |
|
-24.7 |
-36.9 |
-106.8 |
-293.0 |
-212.4 |
|
-224.6 |
|
|
OCF, bln rub |
? |
|
-18.2 |
-28.7 |
-7.57 |
-110.8 |
-190.9 |
|
-196.5 |
|
CAPEX, bln rub |
? |
|
0.079 |
0.248 |
0.831 |
53.5 |
9.69 |
|
9.02 |
|
FCF, bln rub |
? |
|
-18.3 |
-28.9 |
-8.40 |
-164.3 |
-200.6 |
|
-205.5 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
25.2 |
36.9 |
123.5 |
314.8 |
218.1 |
|
192.2 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
2.96 |
|
50.7 |
|
R&D, bln rub |
|
|
14.1 |
23.3 |
23.1 |
129.5 |
174.3 |
|
196.8 |
|
Interest expenses, bln rub |
|
|
0.010 |
0.005 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
57.9 |
24.0 |
148.5 |
240.2 |
683.2 |
|
619.8 |
|
Net Assets, bln rub |
? |
|
48.2 |
16.7 |
119.9 |
181.2 |
634.3 |
|
588.7 |
|
Debt, bln rub |
|
|
0.317 |
0.291 |
1.65 |
4.83 |
3.86 |
|
3.69 |
|
Cash, bln rub |
|
|
49.2 |
20.3 |
138.1 |
217.3 |
653.5 |
|
582.7 |
|
Net debt, bln rub |
|
|
-48.9 |
-20.0 |
-136.5 |
-212.5 |
-649.6 |
|
-579.0 |
|
|
Ordinary share price, rub |
|
|
13.0 |
2.21 |
10.7 |
10.6 |
21.5 |
|
19.9 |
|
Number of ordinary shares, mln |
|
|
11.5 |
12.1 |
19.8 |
58.6 |
87.4 |
|
113.1 |
|
|
Market cap, bln rub |
|
|
150 |
27 |
212 |
623 |
1 876 |
|
2 251 |
|
EV, bln rub |
? |
|
101 |
7 |
76 |
410 |
1 227 |
|
1 672 |
|
Book value, bln rub |
|
|
48 |
17 |
120 |
181 |
634 |
|
589 |
|
|
EPS, rub |
? |
|
-2.14 |
-3.04 |
-5.38 |
-5.00 |
-2.43 |
|
-1.99 |
|
FCF/share, rub |
|
|
-1.59 |
-2.39 |
-0.42 |
-2.80 |
-2.30 |
|
-1.82 |
|
BV/share, rub |
|
|
4.18 |
1.37 |
6.04 |
3.09 |
7.26 |
|
5.20 |
|
|
EBITDA margin, % |
? |
|
|
|
-199.7% |
-1 674% |
-3 042% |
|
-5 810% |
|
Net margin, % |
? |
|
|
|
-761.9% |
-3 240% |
-3 060% |
|
-5 594% |
|
FCF yield, % |
? |
|
-12.2% |
-108.0% |
-3.96% |
-26.4% |
-10.7% |
|
-9.13% |
|
ROE, % |
? |
|
-51.3% |
-221.6% |
-89.1% |
-161.7% |
-33.5% |
|
-38.2% |
|
ROA, % |
? |
|
-42.7% |
-153.4% |
-71.9% |
-121.9% |
-31.1% |
|
-36.2% |
|
|
P/E |
? |
|
-6.05 |
-0.73 |
-1.99 |
-2.13 |
-8.83 |
|
-10.0 |
|
P/FCF |
|
|
-8.17 |
-0.93 |
-25.3 |
-3.79 |
-9.35 |
|
-11.0 |
|
P/S |
? |
|
|
|
15.1 |
68.9 |
270.3 |
|
560.8 |
|
P/BV |
? |
|
3.10 |
1.61 |
1.77 |
3.44 |
2.96 |
|
3.82 |
|
EV/EBITDA |
? |
|
-4.12 |
-0.19 |
-2.71 |
-2.71 |
-5.81 |
|
-7.17 |
|
Debt/EBITDA |
|
|
2.00 |
0.55 |
4.87 |
1.40 |
3.08 |
|
2.48 |
|
|
R&D/CAPEX, % |
|
|
17 861% |
9 384% |
2 778% |
242.1% |
1 800% |
|
2 181% |
|
|
CAPEX/Revenue, % |
|
|
|
|
5.93% |
591.8% |
139.5% |
|
224.7% |
|
| Immunome shareholders |
